Dorothee Nickles
Dorothee Nickles
Verified email at
Cited by
Cited by
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients
A Palanichamy, S Jahn, D Nickles, M Derstine, A Abounasr, SL Hauser, ...
The Journal of Immunology 193 (2), 580-586, 2014
A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes
M Brechmann, T Mock, D Nickles, M Kiessling, N Weit, R Breuer, W Müller, ...
Immunity 37 (4), 697-708, 2012
Genetics of multiple sclerosis: swimming in an ocean of data
SE Baranzini, D Nickles
Current opinion in neurology 25 (3), 239-245, 2012
Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls
D Nickles, HP Chen, MM Li, P Khankhanian, L Madireddy, SJ Caillier, ...
Human molecular genetics 22 (20), 4194-4205, 2013
An RNAi screen identifies USP2 as a factor required for TNF‐α‐induced NF‐κB signaling
M Metzig, D Nickles, C Falschlehner, J Lehmann‐Koch, BK Straub, ...
International journal of cancer 129 (3), 607-618, 2011
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
H Xiong, S Mittman, R Rodriguez, M Moskalenko, P Pacheco-Sanchez, ...
Cancer research 79 (7), 1493-1506, 2019
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease
GP Parnell, PN Gatt, M Krupa, D Nickles, FC McKay, SD Schibeci, ...
Clinical immunology 151 (1), 16-24, 2014
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC …
JE Rosenberg, DP Petrylak, MS Van Der Heijden, A Necchi, ...
Journal of Clinical Oncology 34 (15_suppl), 104-104, 2016
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
FA Legrand, DR Gandara, S Mariathasan, T Powles, X He, W Zhang, ...
Journal of Clinical Oncology 36 (15_suppl), 12000-12000, 2018
A genome-wide RNA interference screen identifies caspase 4 as a factor required for tumor necrosis factor alpha signaling
D Nickles, C Falschlehner, M Metzig, M Boutros
Molecular and cellular biology 32 (17), 3372-3381, 2012
In depth comparison of an individual’s DNA and its lymphoblastoid cell line using whole genome sequencing
D Nickles, L Madireddy, S Yang, P Khankhanian, S Lincoln, SL Hauser, ...
BMC genomics 13 (1), 1-11, 2012
Sequencing of the IL6 gene in a case–control study of cerebral palsy in children
P Khankhanian, SE Baranzini, BA Johnson, L Madireddy, D Nickles, ...
BMC medical genetics 14 (1), 1-8, 2013
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis
NL Fewings, PN Gatt, FC McKay, GP Parnell, SD Schibeci, J Edwards, ...
Journal of autoimmunity 78, 57-69, 2017
Coexpression of inhibitory receptors enriches for activated and functional CD8+ T cells in murine syngeneic tumor models
H Xiong, S Mittman, R Rodriguez, P Pacheco-Sanchez, M Moskalenko, ...
Cancer immunology research 7 (6), 963-976, 2019
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
T Powles, D Nickles, E Van Allen, C Chappey, W Zou, M Kowanetz, ...
Journal for ImmunoTherapy of Cancer 3 (2), 1-2, 2015
End-stage dying glioma cells are engulfed by mouse microglia with a strain-dependent efficacy
D Nickles, A Abschuetz, H Zimmer, T Kees, R Geibig, E Spiess, ...
Journal of neuroimmunology 197 (1), 10-20, 2008
NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes
A Singh, A Daemen, D Nickles, SM Jeon, O Foreman, K Sudini, F Gnad, ...
Clinical Cancer Research 27 (3), 877-888, 2021
The system can't perform the operation now. Try again later.
Articles 1–20